Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan
Research Article
Development of Assaying Plasma TDP-43 Utilizing Immunomagnetic Reduction
Author(s): Shieh-Yueh Yang*, Heui-Chun Liu, Chin-Yi Lin, Ming-Jang Chiu, Ta-Fu Chen, Chin-Hsien Lin and Hsin-Hsien Chen
TDP-43 is a promising biomarker for frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). However, studies on TDP-43 in
human biofluid are rare. In this work, the authors utilized an ultrasensitive technology, called immunomagnetic reduction (IMR), to develop the
reagent for assaying TDP-43. The preclinical performance characteristics of the TDP-43 reagent, such as the standard curve, detection limits,
assay linearity, dilution recovery range, assay reproducibility, spike recovery, reagent stability, and interference tests, were explored according to
the CLSI guidelines. Plasma samples from normal controls (NC, n = 27) and from patients with frontotemporal dementia (FTD, n = 9), Alzheimer’s
disease (AD, n = 34) and Parkinson’s disease (PD, n = 10) were collected for TDP-43 assays using the IMR TDP-43 reagent. The low-detection
limit.. Read More»
Neurological Disorders received 1343 citations as per Google Scholar report